Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims:
In a healthy person, the kidneys are responsible for filtering out the waste products and excess water in the blood, and converting them into urine. If the kidneys suddenly stop working (acute kidney injury) or are suffering from severe, long-term disease of the kidneys (chronic kidney failure) then the body is unable to get rid of the waste products building up in the blood. Eventually, the kidneys are no longer able to support the body’s needs (end stage renal disease) and so a treatment to replace the work of the failed kidneys is needed. Kidney transplantation is the best treatment for end-stage renal disease. Kidneys harvested from deceased donors are already damaged before transplantation, both during storage (cold ischemia time) and the surgical procedure itself (warm ischemia time). There is currently a lack of information concerning the influence of warm and cold ischemia on kidney tissue. It is possible to eliminate warm ischemia using specially designed cooling system during kidney transplantation (ice bag technique, IBT). The aim of the study is to investigate whether elimination of warm ischemia will improve kidney allograft function and survival. The study will also assess the immune-related gene expression in kidney biopsy samples taken during transplantation.

Who can participate?
Adult kidney transplant candidates on an active waiting list for a new kidney who will have their surgery at Wroclaw Medical University Hospital.

What does the study involve?
Kidney recipients are randomly assigned to one of two groups. Those in the first group receive donor kidneys stored using the ice bag technique (IBT). This is in the form of a special bag, in which the kidney is placed in a central compartment with compartments of ice-cooled sterile saline (salt water) on either side, which is then placed on melting slushed ice. Those in the second group receive a kidney from the same donor, which is stored using the standard technique (no extra cooling). Participants in both groups attend follow up visits 7 days, 14 days, 1 month, 3 months, 6 months, 12, months, 18 months, 24 months and 60 months after their surgery in order for the functioning of the new kidney and any side effects to be assessed. In addition, for participants in both groups, three samples are taken of the transplanted kidney immediately after the organ is recovered from the host, immediately before transplantation, and 30 minutes after the kidney has been transplanted in order to measure levels of immune system genes in the organ.

What are the possible benefits and risks of participating?
There will be no immediate direct benefit to those taking part, but there should be benefits to future transplant recipients if the study confirm that using ice bag technique improves the short- as well as long-term results of kidney transplantation. By taking part in this study there are no risks of physical injury or harm other than standard risk related to kidney transplantation procedure.

Where is the study run from?
Wroclaw Medical University Hospital

When is study starting and how long is it expected to run for?
August 2005 to December 2011

Who is funding the study?
The Polish Ministry of Science and Higher Education (Poland)

Who is the main contact?
Dr Dorota Kamińska

Trial website

Contact information



Primary contact

Dr Dorota Kamińska


Contact details

Uniwersytecki Szpital Kliniczny we Wrocławiu
Borowska 213

Additional identifiers

EudraCT number number

Protocol/serial number

2 P05B 165 29

Study information

Scientific title

Second warm ischemia elimination in kidney transplantation - structural and immunological changes in transplanted kidneys


Study hypothesis

Null hypothesis:
There will be no significant differences between the interventions with regards to graft function and survival, recipient function and survival, and intragraft immune-related gene expression.

Ethics approval

Commission of Bioethics at Wroclaw Medical University, 13/01/2005, ref: 36/2005

Study design

Single-centre randomised parallel trial

Primary study design


Secondary study design

Randomised parallel trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Kidney transpantation


Patients who fulfill the selection criteria and are willing to participate will be asked to complete a consent form, after reading a participant information leaflet. Treatment allocation is performed centrally at Department of Vascular, General and Transplant Surgery. The duration of participants in the trial is up to 60 months. All kidney allograft recipients were randomly assigned before transplantation to one of two groups

Group 1: Participants receive donor kidneys stored using the ice bag technique (IBT). This involves using a specially designed disposable polyethylene bag produced by Raguse GmbH (Germany). The kidneys were prepared for implantation on the back table and put into a polyethylene bag in order to eliminate warm ischemia. The bag consisted of three compartments. The middle compartment homing the graft was surrounded by two external compartments filled with ice-cooled sterile saline and placed on the melting slushed ice. After placing the graft in the middle compartment the renal vein and artery were pulled outside the bag via a small hole in the middle compartment. Then the vascular renal vein and renal artery were anastomosed to the iliac vein and artery. After completion of the vascular anastomoses followed by graft reperfusion the polyethylene bag was removed from the transplanted kidney.

Group 2: Participants receive the contralateral kidneys from the same donorsusing the standard technique, which do not involve the extra cooling.

Except the use of IBT the pre- as well as post-transplant treatment do not differ between study groups. For both groups, during the transplantation procedure, three consecutive kidney core biopsies are obtained with a 16 G automatic needle (TSK Laboratory, Japan) at the following timepoints:
1. Immediately after organ recovery - biopsy 1 (B1)
2. After organ storage and cold ischemia, on the back table, before the transplantation procedure -biopsy 2 (B2)
3. Approximately 30 minutes after reperfusion -biopsy 3 (B3)

Participants in both groups attend follow up visits 7 days, 14 days, 1 month, 3 months, 6 months, 12, months, 18 months, 24 months and 60 months post-transplant. On each of these visits, the following clinical parameters are assessed: side-effects, graft survival, delayed graft function, rejection episodes, serum creatinine concentration, eGFR (estimated by MDRD formula), urine analysis, overall patient survival.

Intervention type



Drug names

Primary outcome measure

1. Graft function is determined by measuring eGFR (using MDRD formula) at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation
2. Graft survival is measured through medical record review and patient urine output 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation
3. Delayed graft function rate is assessed through reviewing patient notes for dependence on haemodialysis at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation
4. Rejection episode rate is determined through medical note review at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation

Secondary outcome measures

Relationship between intragraft gene expression (B1,B2,B3) and post-transplant clinical parameters (patient and graft survival, graft function described as eGFR, delayed graft function and acute rejection episodes) are assessed at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Kidney transplant candidate on active waiting list assigned to transplantation in Wroclaw Medical University Hospital
2. Aged 18 years and over
3. Provision of written informed consent

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Decline participation in this study
2. Unable to comply with requirements of this study protocol

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Wroclaw Medical University Hospital
Transplantation Center Department of Vascular, General and Transplant Surgery and Department of Nephrology and Transplantation Medicine Borowska 213

Sponsor information


The Polish Ministry of Science and Higher Education

Sponsor details

20 Hoża Street
1/3 Wspólna Street

Sponsor type




Funder type


Funder name

The Polish Ministry of Science and Higher Education

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Results were published as abstract:
1. Dorota Kamińska, Paweł Chudoba, Katarzyna Kościelska-Kasprzak, Agnieszka Lepiesza, Agnieszka Gomułkiewicz, Piotr Dzięgiel, Agnieszka Hałoń, Marian Klinger.: Gene expression in the deceased donor kidney determinates allograft function
Transpl.Int. 2015 Vol.28 suppl.4; s.158 poz.BO85
17th Congress of the European Society for Organ Transplantation. Brussels (Belgium), 13-16 September 2015.

Intention to publish date

Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes